.png "Endologix Inc (NASDAQ: ELGX)")
In a report released today, Steven Lichtman from Oppenheimer maintained a Hold rating on Endologix Inc (NASDAQ: ELGX). The company’s shares closed yesterday at $1.72, close to its 52-week low of $1.64.
According to TipRanks.com, Lichtman is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.9% and a 52.1% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Endologix Inc with a $4 average price target, which is a 132.6% upside from current levels. In a report released today, Piper Jaffray also maintained a Hold rating on the stock with a $3 price target.
.
See today’s analyst top recommended stocks >>
Based on Endologix Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $23.88 million. In comparison, last year the company had a GAAP net loss of $14.27 million.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ELGX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA.
